Parexel partners up for clinical trial education

CRO giant Parexel International ($PRXL) has unveiled three new education programs in partnership with schools around the world, lending its expertise in hopes of training the next generation of clinical researchers.

The new efforts, part of what the company calls Parexel Academy, offer degree and certificate programs taught by the CRO's in-house experts. At the Medical School Berlin, Parexel is contributing to a bachelor of science program in clinical research, at the same time participating in a postgraduate certificate in clinical trial management at Massachusetts' Salem State University and a research and management program at Kyoto Pharmaceutical University in Japan.

Parexel's education effort has been running for more than a decade, the company said, collaborating with schools in the U.S., Europe and Asia. More than 1,000 students have graduated from Parexel Academy's programs, moving on to join the next generation of clinical professionals, according to the CRO.

"Through the Parexel Academy, we tailor educational and degree programs with our partners to equip the future health sciences workforce with a holistic and cross-functional foundation in clinical research and clinical trial management," Senior Director Heidrun Bruchmann said in a statement.

Meanwhile, Parexel has dimmed its expectations for fiscal 2015 after some disappointing sales and currency exchange hindrances. The CRO is expecting about $2 billion in 2015 revenue, a roughly 2% reduction from the $2.1 billion it forecast back in October.

- read the statement

Suggested Articles

The platform uses wearables to continuously collect clinical data from study participants and applies machine learning to analyze the data.

St. Jude, Microsoft and DNAnexus have created a data-sharing and analysis platform to help accelerate pediatric cancer research.

Charles River partners with PathoQuest to offer clients NGS solutions for biologics viral contamination testing and cell-line genetic characterization.